Universal Nutriscience Pvt Ltd ( UNS) announced on September 30 the completion of the acquisition of all assets pertaining to the nutraceuticals business of Sanofi India Limited through a slump sale process. UNS is a strategic partnership between Kedaara Capital (one of India’s leading private equity firms) and Universal Medicare (a pioneer in Nutraceuticals).
On July 17, Moneycontrol was the first to report that a consortium of Universal Medicare and Kedaara Capital had emerged as the front-runners to acquire select brands of Sanofi India, chiefly the nutraceutical portfolio.
According to an official statement, the vision of UNS is to build India's leading nutraceuticals and wellness company through a world-class, science-driven portfolio of products, with the help of a talented and highly engaged team. The company is backed by over three decades of expertise in manufacturing and R&D, dedicated exclusively to nutraceuticals, including several first-to-market launches.
The complete nutraceutical portfolio consisting of 16 brands, including market leaders such as Seacod®, ECod®, CoQ®, Primosa®, Collaflex®, along with most of the employees engaged in the marketing and distribution of these brands, have been seamlessly transferred to UNS effective 30th September 2021.